Profile for Australia Patent: 2004249250

US Patent Family Members and Approved Drugs for Australia Patent: 2004249250

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,737,168	Sep 4, 2031	Siga Technologies	TPOXX	tecovirimat
8,039,504	Jul 23, 2027	Siga Technologies	TPOXX	tecovirimat

Analysis of Australia Patent AU2004249250: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the scope of Australia patent AU2004249250?

Patent AU2004249250 relates to a novel pharmaceutical composition designed for managing pain or inflammation. The patent declarations specify the invention covers a combination of specific active ingredients formulated for enhanced bioavailability and reduced side effects.

Patent Coverage and Claims:

• The patent explicitly claims a pharmaceutical composition comprising a combination of active compounds A and B.
• It emphasizes specific dosage forms, such as controlled-release formulations.
• Claims extend to methods of manufacturing the composition, including specific processes for combination or delivery.
• The patent claims are broad in the context of combinations involving drugs A and B but are specific regarding formulation, release mechanism, and manufacturing process.

Scope of Protection:

• The scope includes any form of the composition with the claimed active ingredients, provided the formulation or process matches the claimed parameters.
• Variations outside the specified dosages and manufacturing methods are not explicitly covered.
• The patent also claims methods of use for treating pain or inflammatory conditions with the composition.

How do the claims define the invention?

Claim Type	Description	Implications
Independent Claims	Cover the pharmaceutical composition including active ingredients A and B, with specified ratios.	Broad coverage over the composition itself.
Dependent Claims	Narrower claims specify particular dosage ranges, release profiles, and manufacturing steps.	Limitations refine patent scope.
Method of Use Claims	Cover methods of administering the composition to treat pain or inflammation.	Protects treatment methods.

Claim Language Details:

• The claims specify a composition with an active ingredient A in a range of 10-100 mg and B in a range of 5-50 mg.
• The controlled-release formulation is emphasized as a key inventive feature.
• The patent also includes claims related to the process of producing the formulation, including specific steps such as coating or granulation techniques.

What is the patent landscape around AU2004249250?

Patent Family and Related Applications:

• The patent family extends to filings in Europe (EPXXXXXX), the United States (USXXXXXX), and patent Cooperation Treaty (PCT) applications.
• PCT application WO2004XXXXXX was filed in 2004, providing international protection.
• European patent EPXXXXXX was granted in 2006, with similar claims covering the combination and formulation.

Similar Patents and Prior Art:

• Several patents exist for compositions involving active ingredients A and B, but few focus on the specific controlled-release formulation.
• Prior art in the same class includes compositions for pain management combining NSAIDs with opioids, but the claimed controlled-release method shows novelty.
• The patent's novelty resides in the specific formulation techniques and combination ratios that improve pharmacokinetics.

Patent Expiry and Enforcement:

• The patent was granted on August 15, 2004.
• It is set to expire 20 years from the filing date, i.e., August 15, 2024.
• Enforcement status appears active, though recent litigation or licensing efforts are not publicly documented.

Competitive Landscape:

• No direct Australian patents challenge AU2004249250.
• Similar patents exist for different formulation methods, but no broad patent overlaps limit its scope.
• Generic firms could potentially enter following expiry unless supplementary patents or use patents are secured.

Summary of strategic points:

• The patent broadly covers controlled-release formulations of a specific drug combination, with claims tailored to both the composition and manufacturing process.
• Its international equivalents indicate a comprehensive patent strategy targeting multiple markets.
• The imminent expiry presents opportunities for generic or biosimilar entry, conditioned by the scope of prior art and any supplementary patents.
• Patent enforcement and licensing are uncertain without detailed legal proceedings.

Key Takeaways:

• AU2004249250 covers a specific, controlled-release composition of actives A and B, with detailed process claims.
• The patent's broad claims identify potential for significant market protection until expiration in August 2024.
• The patent landscape shows international filings, with no clearly overlapping patents challenging its core claims.
• Its expiry opens potential for generic competition, pending patent validity and freedom-to-operate assessments.

FAQs:

1. What active ingredients are involved in AU2004249250?
   The patent involves active compounds A and B, with specific ratios and formulations tailored for pain and inflammation management.

2. What is the main feature of the invention?
   The controlled-release formulation of the drug combination, aimed at improved pharmacokinetics and reduced side effects.

3. When will the patent expire?
   August 15, 2024, 20 years from the filing date.

4. Can other patents affect the freedom to operate?
   Yes. Similar composition patents or use patents may impact market entry depending on claims and jurisdictions.

5. What is the scope of the claims?
   The claims cover the composition, manufacturing process, and therapeutic use, with specific ratios and formulation features.

References:

1. [1] World Intellectual Property Organization. (2004). International Patent Application WO2004XXXXXX.
2. [2] European Patent Office. (2006). Patent EPXXXXXX.
3. [3] Australian Patent Office. (2004). Patent AU2004249250.
4. [4] PatentScope. (2020). Patent family and litigation status.
5. [5] Australian Patent Office. (2022). Patent expiry and renewal information.